661481-04-5

Basic information

• Product Name: 4-(4-benzyloxy-2-methylphenylmethyl)-1,2-dihydro-5-isopropyl-3H-pyrazol-3-one
• Synonyms: 4-(4-benzyloxy-2-methylphenylmethyl)-1,2-dihydro-5-isopropyl-3H-pyrazol-3-one
• CAS NO: 661481-04-5
• Molecular Weight: 336.434
• Mol File: 661481-04-5.mol

Chemical Properties

• CAS DataBase Reference: 4-(4-benzyloxy-2-methylphenylmethyl)-1,2-dihydro-5-isopropyl-3H-pyrazol-3-one(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-benzyloxy-2-methylphenylmethyl)-1,2-dihydro-5-isopropyl-3H-pyrazol-3-one(661481-04-5)
• EPA Substance Registry System: 4-(4-benzyloxy-2-methylphenylmethyl)-1,2-dihydro-5-isopropyl-3H-pyrazol-3-one(661481-04-5)

Safety Data

• Hazardous Substances Data: 661481-04-5(Hazardous Substances Data)

Upstream product

• 167479-46-1 4-benzyloxy-2-methylphenylmethanol 
• 42558-54-3 Methyl 4-methyl-3-oxopentanoate 
• 661481-05-6 (4-benzyloxy-2-methylphenyl)methyl mesylate 
• 1410807-01-0 C₂₂H₂₆O₄ 
• 124-63-0 methanesulfonyl chloride 
• 7152-15-0 ethyl 4-methyl-3-oxo-pentanoate 

Downstream Products

• 667937-82-8 4-(4-benzyloxy-2-methylphenylmethyl)-5-isopropyl-1H-pyrazol-3-yl 2,3,4,6-tetra-O-acetyl-β-d-glucopyranoside 
• 667937-85-1 4-(4-benzyloxy-2-methylphenylmethyl)-5-isopropyl-1H-pyrazol-3-yl β-d-glucopyranoside 
• 667937-69-1 4-(4-hydroxy-2-methylphenylmethyl)-5-isopropyl-1H-pyrazol-3-yl β-d-glucopyranoside 

Relevant articles and documents

Structure-activity relationship studies of 4-benzyl-1H-pyrazol-3-yl β-d-glucopyranoside derivatives as potent and selective sodium glucose co-transporter 1 (SGLT1) inhibitors with therapeutic activity on postprandial hyperglycemia

Sodium glucose co-transporter 1 (SGLT1) plays a dominant role in the absorption of glucose in the gut and is considered a promising target in the development of treatments for postprandial hyperglycemia. A series of 4-benzyl-1H-pyrazol-3-yl β-d-glucopyran

PYRAZOLE DERIVATIVES, MEDICINAL COMPOSITION CONTAINING THE SAME, MEDICINAL USE THEREOF, AND INTERMEDIATE FOR PRODUCTION THEREOF

The present invention provides pyrazole derivatives represented by the general formula: wherein R1 represents H, an optionally substituted C1-6 alkyl group etc.; one of Q and T represents a group represented by the general formula: or a group represented by the general formula: while the other represents an optionally substituted C1-6 alkyl group etc.; R2 represents H, a halogen atom, OH, an optionally substituted C1-6 alkyl group etc.; X represents a single bond, O or S; Y represents an optionally substituted C1-6 alkylene group etc.; Z represents -RB, -CORC etc. in which RB represents an optionally substituted C1-6 alkyl group etc.; and RC represents an optionally substituted C1-6 alkyl group etc.,; R4 represents H, an optionally substituted C1-6 alkyl group etc.; and R3, R5 and R6 represent H, a halogen atom etc., pharmaceutically acceptable salts thereof or prodrugs thereof, which exhibit an excellent inhibitory activity in human SGLT1 and are useful as agents for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, impaired glucose tolerance, impaired fasting glycemia, diabetic complications or obesity, and a disease associated with the increase of blood galactose level such as galactosemia, and pharmaceutical compositions comprising the same, pharmaceutical uses thereof, and intermediates for production thereof.

PYRAZOLE DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, MEDICINAL USE THEREOF, AND INTERMEDIATE FOR PRODUCTION THEREOF

The present invention provides pyrazole derivatives represented by the general formula: wherein R1 represents H, an optionally substituted C1-6 alkyl group etc.; one of Q and T represents a group represented by the general formula: or a group represented by the general formula: while the other represents an optionally substituted C1-6 alkyl group etc.; R2 represents H, a halogen atom, OH, an optionally substituted C1-6 alkyl group etc.; X represents a single bond, O or S; Y represents a single bond, a C1-6 alkylene group etc. ; Z represents CO or SO2; R4 and R5 represent H, an optionally substituted C1-6 alkyl group etc.; and R3, R6 and R7 represent H, a halogen atom etc., pharmaceutically acceptable salts thereof or prodrugs thereof, which exhibit an excellent inhibitory activity in human SGLT1 and are useful as agents for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, diabetic complications or obesity, and pharmaceutical compositions comprising the same, pharmaceutical uses thereof, and intermediates for production thereof.